

**The 2nd ILEP Symposium on the Optimal Lipid Lowering
Management of patients at very high CVD risk, Lodz, Poland
(22nd April 2024)**



11.30 - 12.00. Welcome coffee and tea

12.00 – 13.15. SESSION 1: Intensive statin therapy vs intensive lipid lowering combination therapy - why does this switch is necessary?

Chairs: Prof. Jacek Józwiak (Poland), Prof. Ivan Pećin (Croatia)

12.00 - 12.15. Lipid disorders in Europe – where we are in 2024 and why we are so ineffective?
(Prof. Daniel Pella, Slovak Republic)

12.15 – 12.30. Effective diagnosis of lipid disorders. LDL-C, non-HDL or ApoB? What new PSDL/PoLA 2024 recommendations say on this? *(Prof. Anca Stoian, Romania)*

12.30 – 12.45. Intensive statin therapy vs combination lipid lowering therapy? 20 years of experience, 20 years of failure? *(Prof. Michal Vrablik, Czechia).*

12.45 – 13.00. Optimal, upfront lipid lowering combination therapy in ACS patients peri-procedurally and early during the hospitalization - how, when and what data do we have?
(Prof. Dariusz Dudek, Poland).

13.00 – 13.15. Discussion.

13.15 – 14.30. SESSION 2: Recent results and the place of new drugs in lipid lowering therapy - bempedoic acid, PCSK9 inhibitors, inclisiran, perspective drugs.

Chairs: Prof. Michal Vrablik (Czechia), Prof. Robert Gil (Poland)

13.15 – 13.30. Most recent data on PCSK9 inhibitors in the lipid disorders management. The way to be finally effective for selected (unfortunately) patients? *(Prof. Dov Gavish, Israel)*

13.30 – 13.45. The place of PCSK9 modulators (PCSK9Is and inclisiran) in the lipid lowering therapy. Another way to be on LDL-C target? *(Prof. Charalambos Vlachopoulos, Greece).*

13.45 – 14.00. The place and role of the bempedoic acid in the lipid lowering management. Statin intolerant, high risk patients, or both? *(Prof. Maciej Banach, Poland)*

14.00 – 14.15. Obicetrapib, oral PCSK9, CRISPR, vaccines, and their possible perspective role in LLT *(Prof. Gustavs Latkovskis, Latvia)*

14.15 – 14.30. Discussion.

14.30 – 15.15. Light Lunch and Networking

15.15 – 16.30. SESSION 3: How to increase the number of patients treated with innovative therapies and overcome the reimbursement criteria. Can we learn from each other?

Chairs: Prof. Gustavs Latkovskis, (Latvia), Prof. Charalambos Vlachopoulos (Greece)

15.15 - 15.30. The current situation on the reimbursement criteria of PCSK9 modulators in CEE and other European countries. Can we learn from each other to be more effective? (*Prof. Piotr Jankowski, Poland*)

15.30 – 15.45. Lipid lowering therapy and atheroma plaque. Angio-CT, CAC score, soft atheroma plaque – whether they may help to extend indications for innovative therapies? (*Prof. Robert Gil, Poland*)

15.45 – 16.00. New guidelines on Lp(a). The role in CVD risk assessment and way to reduce it. Whether Lp(a) should be also included in PCSK9ms reimbursement programs? (*Prof. Ivan Pećin, Croatia*)

16.00 – 16.15. Very high-risk primary prevention patients, high risk ASCVD patients without an event – why cannot they benefit from the innovative therapies? Do we have data to support these indications? (*Prof. Krzysztof Dyrbuś, Poland*)

16.15 – 16.30. Discussion.

16.30-17.45. SESSION 4: Whether and how can we overcome the well-recognized obstacles of ineffective management, like nonadherence, therapeutical inertia, statin intolerance, lack of drugs availability, lack of knowledge.

Chairs: Prof. Daniel Pella (Slovakia), Prof. Agata Bielecka-Dąbrowa (Poland)

16.30 – 16.45. Non-adherence as an independent CVD risk factor. How to optimally measure therapy adherence and the ways to improve this. (*Prof. Marek Gierlotka, Poland*)

16.45 – 17.00. Management of statin intolerance in 2024. Can we be effective with LDL-C goal achievement in most of the patients? (*Prof. Peter Penson, UK*)

17.00 – 17.15. Lipid lowering therapy in challengeable groups of patients – T2DM and elderly. Whether (upfront) lipid lowering combination therapy might be a solution? (*Prof. Dan Gaita, Romania*)

17.15 – 17.30. Patients with metabolic disorders and/or statin intolerance. Pitavastatin – the way to personalize lipid lowering therapy ? (*Prof. Niki Katsiki, Greece*)

17.30 – 17.45. Discussion.

17.45- 17.55. Short coffee break

17.55 – 18.55. SESSION 5: Presentation of the 2024 ILEP Position Paper on the Optimal use of lipid-lowering therapy in very high and extremely high-risk patients.

Chairs: Prof. Niki Katsiki (Greece), Prof. Anca Stoian (Romania)

17.55 – 18.20. 2024 ILEP Position Paper on the Optimal use of lipid-lowering therapy in very high and extremely high-risk patients. (*Prof. Maciej Banach, Poland*)

18.20 – 18.45. Round-table debate and discussion (all the experts)

18.45 - 19.00. Take-home Conclusions